相关实验视频
Updated: Jul 9, 2025

04:20
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
Published on: February 9, 2024
959
宫癌中FA-BRCA途径的下调在化学耐受性发展期间逐渐逆转:临床影响
Priyanka Dutta1, Debolina Pal1, Farhin Sultana1
1Department of Oncogene Regulation, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Kolkata, 700026, West Bengal, India.
Reproductive sciences (Thousand Oaks, Calif.)
|November 27, 2023
概括
对于宫癌 (CACX) 的发展,FA-BRCA通路被禁用. 然而,其基因在化学耐受性瘤中被上调,预测预后不佳和复发风险.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
背景情况:
- 子宫癌 (CACX) 仍然是女性的主要全球健康问题.
- 驱动CACX和治疗耐药性的分子机制尚未完全理解.
研究的目的:
- 在CACX发育过程中对FA-BRCA通路的关键调节基因进行功能性评估.
- 研究这些基因在化疗耐受性和患者预后中的作用.
主要方法:
- 在正常和瘤组织中分析FA-BRCA基因分子谱.
- 在体验证,血循环瘤细胞 (CTC) 分析,以及体外西斯治疗.
- 对DNA甲基化,基因删除和DNA损伤标记 (γ-H2X) 的评估.
主要成果:
- 随着CACX的进展,FA-BRCA基因表达减少,这与促进物甲基化和删除有关.
- 血CTC中促进体甲基化的增加与CACX预后不佳相关.
- 对FA-BRCA基因的上调预测了化疗耐受性,并与减少的DNA损伤标记物有关.
结论:
- 在CACX启动过程中,FA-BRCA通路的失活至关重要.
- 增加FA-BRCA基因表达有助于化疗耐受性,并可能预测疾病复发.
相关概念视频
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Negative Regulator Molecules
35.4K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K

